Learn how PROTACs (Proteolysis Targeting Chimeras) and targeted protein degraders are transforming small molecule drug design by eliminating disease-causing proteins, enabling catalytic, durable pharmacology across oncology, immunology, and other therapeutic areas.
Learn what retatrutide is, how its triple agonist action on GLP‑1, GIP, and glucagon receptors works, and why early clinical trials show up to 24% weight loss and major improvements in blood sugar control.
Discover how AI and machine learning are transforming pharmacovigilance—from manual safety case review to intelligent signal detection. Learn how NLP, real‑world data, and predictive models improve adverse event detection, signal prioritization, and proactive drug safety monitoring.
Learn how tirzepatide, a next‑generation dual GIP/GLP‑1 receptor agonist, uses advanced peptide engineering to deliver powerful glycemic control and bariatric‑level weight loss in type 2 diabetes, outperforming traditional GLP‑1 drugs.
Discover how molecular glues are transforming drug discovery by enabling targeted protein degradation of previously “undruggable” targets. Learn their mechanism, advantages over PROTACs, and emerging AI‑driven design strategies in oncology and immunology.
Discover how AI and machine learning are revolutionizing pharmacovigilance, from automated case intake and MedDRA coding to real-time signal detection across clinical trials, EHRs, and patient-generated data for faster, more accurate drug safety monitoring.
Learn why retatrutide (LY3437943), Eli Lilly’s next-generation triple-agonist targeting GLP-1, GIP, and glucagon receptors, is the most watched obesity drug candidate today, promising deeper, faster weight loss and improved metabolic health.
Discover how AI and machine learning are transforming pharmacovigilance by automating case processing, enhancing signal detection across multi-source safety data, and helping drug safety teams scale while maintaining compliance and protecting patients.
Discover how oral small molecule GLP‑1 receptor agonists could replace weekly injections like semaglutide and tirzepatide, offering scalable, room‑temperature‑stable pills that transform obesity and type 2 diabetes care worldwide.
Learn how tirzepatide, a dual GIP and GLP‑1 receptor agonist, delivers powerful blood sugar control and significant weight loss, redefining treatment standards for type 2 diabetes and obesity.